Evidence map›Paper›PMID 38578822›Full record

ArticlePloS one2024

Using a data-driven approach to define post-COVID conditions in US electronic health record data.

Kathleen M Andersen, Farid L Khan, Peter W Park, Timothy L Wiemken, Birol Emir, Deepa Malhotra, Tuka Alhanai, Mohammad M Ghassemi, Leah J McGrath

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Self-reported Long COVID and its Determinants in a Rural North Indian Adult Population: Lessons Learnt from the Pandemic.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathleen M AndersenVaccines Real World Evidence, Pfizer Inc, New York, New York, United States of America.ORCID 0000-0003-2670-800X
Farid L KhanGlobal Medical Affairs, Pfizer Inc, New York, New York, United States of America.
Peter W ParkGlobal Medical Affairs, Pfizer Inc, New York, New York, United States of America.
Timothy L WiemkenGlobal Medical Affairs, Pfizer Inc, New York, New York, United States of America.
Birol EmirGlobal Biometrics and Data Management, Pfizer Inc, New York, New York, United States of America.
Deepa MalhotraVaccines Real World Evidence, Pfizer Inc, New York, New York, United States of America.
Tuka AlhanaiGhamut Corporation, East Lansing, Michigan, United States of America.
Mohammad M GhassemiGhamut Corporation, East Lansing, Michigan, United States of America.
Leah J McGrathVaccines Real World Evidence, Pfizer Inc, New York, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo create a data-driven definition of post-COVID conditions (PCC) by directly measure changes in symptomatology before and after a first COVID episode. MATERIALS AND

methodsRetrospective cohort study using Optum® de-identified Electronic Health Record (EHR) dataset from the United States of persons of any age April 2020-September 2021. For each person with COVID (ICD-10-CM U07.1 "COVID-19" or positive test result), we selected up to 3 comparators. The final COVID symptom score was computed as the sum of new diagnoses weighted by each diagnosis' ratio of incidence in COVID group relative to comparator group. For the subset of COVID cases diagnosed in September 2021, we compared the incidence of PCC using our data-driven definition with ICD-10-CM code U09.9 "Post-COVID Conditions", first available in the US October 2021.

resultsThe final cohort contained 588,611 people with COVID, with mean age of 48 years and 38% male. Our definition identified 20% of persons developed PCC in follow-up. PCC incidence increased with age: (7.8% of persons aged 0-17, 17.3% aged 18-64, and 33.3% aged 65+) and did not change over time (20.0% among persons diagnosed with COVID in 2020 versus 20.3% in 2021). For cases diagnosed in September 2021, our definition identified 19.0% with PCC in follow-up as compared to 2.9% with U09.9 code in follow-up.

conclusionSymptom and U09.9 code-based definitions alone captured different populations. Maximal capture may consider a combined approach, particularly before the availability and routine utilization of specific ICD-10 codes and with the lack consensus-based definitions on the syndrome.

Indexed as

COVID-19Electronic Health RecordsFemaleHumansInternational Classification of DiseasesMaleMiddle AgedPost-Acute COVID-19 SyndromeRetrospective StudiesUnited States

Identifiers

PMID38578822
PMCPMC10997091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.